BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Biocon Out-Licenses Semaglutide to Ajanta Pharma For 26 Markets

Synopsis:


Biocon has signed an out-licensing agreement with Ajanta Pharma to supply its diabetes drug Semaglutide for marketing in 26 countries, with exclusive rights in 23 and semi-exclusive rights in three nations across Africa, the Middle East and Central Asia.


Source:
Biocon Limited Press Release (NSE Exchange Fillings) | Published on Dec 24, 2025

Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

As quoted in the press release of Biocon (NSE Exchange Filings), on December 23, 2025, the company issued a regulatory filing announcing an agreement with Ajanta Pharma Ltd (Ajanta Pharma), whereby Ajanta Pharma will take over the marketing and Sales of Semaglutide, a Vertical Integrated Drug for Improvement of Glycaemic Control in Adult Patients with Type 2 Diabetes, manufactured by Biocon Limited. 

However, it should be noted that Semaglutide will be marketed throughout 26 African, Middle Eastern and Central Asian nations. Additionally, Biocon Limited classifies Semaglutide as a GLP-1 Receptor Agonist and includes it in its diabetes-care portfolio.

Also read: SJS Enterprises Signs Technology And Supply Deal With BOE Varitronix

BIOCON LIMITED.

Trade

399.9-1.64 (-0.40 %)

Updated - 24 December 2025
406.35day high
DAY HIGH
398.80day low
DAY LOW
2148148
VOLUME (BSE)

Key Takeaways

  • Biocon has entered an out-licensing agreement with Ajanta Pharma for Semaglutide. 

  • The agreement applies to 26 countries across Africa, the Middle East and Central Asia.

  • Ajanta Pharma will have exclusive marketing rights in 23 countries and semi-exclusive rights in three. 

  • Biocon will supply the drug product to Ajanta for commercialisation in the agreed territories. 

  • The deal aligns with Biocon’s strategy to expand its GLP-1 portfolio globally. 

Also read: India Ratings Reaffirms AAA Rating for Reliance Industries

Agreement Structure And Geographic Scope

As defined in the terms of this contract, Biocon will supply Ajanta Pharma Ltd. with Semaglutide and Ajanta Pharma Ltd. will have an exclusive right to market the product in 23 countries and will hold semi-exclusive rights to market the drug in an additional three countries. By doing so, Ajanta Pharma Ltd. will be able to market Semaglutide in Africa, the Middle East and Central Asia.

Ajanta Pharma Ltd. already has extensive experience providing branded generic products in more than 30 different countries; this includes providing branded generic products throughout Africa, the Middle East, South-East Asia, and Central Asia. Ajanta Pharma Ltd. is involved in several therapeutic segments, including cardiology, anti-diabetes, ophthalmology, and general health products.

The agreement provides Biocon with the opportunity to utilize Ajanta Pharma Ltd.'s distribution channels and regulatory support structure to have access to patients that are located in these regions. Additionally, Ajanta Pharma Ltd.'s exclusive and semi-exclusive rights have been designed to create a win-win situation where both parties can be successful; Ajanta has the ability to reach all patients located in these locations while Biocon's operational commitment will not be overly spread out.

Product Focus: Semaglutide

Biocon manufactures Semaglutide, a GLP-1 agonist indicated for better glycemic control in adults with Type 2 Diabetes, and is a provider of vertically integrated Semaglutide from manufacturing through formulation and finish to partner companies, for example, Ajanta Pharmaceuticals. 

Although we have entered an out-licencing arrangement with Ajanta to create their generic version of Semaglutide, Biocon continues to have responsibility for manufacturing the drug.

Market Context For Indian Pharma

Biocon's agreement with Ajanta Pharmaceuticals forms part of the larger movement by many Indian pharmaceutical companies to develop and market generic versions of common medications across many areas, including emerging markets. This flurry of activity is due in large part to the fact that some of the GLP-1 medications will lose patent protection in some countries in early 2026, making way for more generic products to fill that demand in these regions, especially Africa, the Middle East and Central Asia. 

To gain access to the vast majority of the global market and to obtain the requisite government approval and distribution channels, many Indian companies have sought out partnerships and/or licensing arrangements. Most of these agreements also establish exclusive or semi-exclusive marketing territories to provide the parties involved with incentives to work together as a single unit.

Summary Table: Agreement Details

Feature

Details

Drug product

Semaglutide

Out-licensing partner

Ajanta Pharma Ltd

Marketing territories

26 countries

Exclusive rights

23 countries

Semi-exclusive rights

3 countries

Regions

Africa, Middle East, Central Asia

Biocon Share Price Update

Biocon share price stands at ₹402 per share on the BSE as of 23 December 2025 at 03:30 PM IST, up by 0.56%.

Published Date : 24 Dec 2025

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,900+ Cr MTF Book

icon-with-text